Evidence map›Paper›PMID 40079832›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2025

Finely Tuned γ Tracks Medication Cycles in Parkinson's Disease: An Ambulatory Brain-Sense Study.

Aaron Colombo, Elena Bernasconi, Laura Alva, Mario Sousa, Ines Debove, Andreas Nowacki, Camille Serquet, Katrin Petermann, T A Khoa Nguyen, Andreia D Magalhães and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Adaptive Deep Brain Stimulation for Parkinson's Disease: Navigating the Roadblocks to Clinical Implementation.Movement disorders : official journal of the Movement Disorder Society · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Aaron ColomboDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.ORCID https://orcid.org/0009-0002-3818-5242
Elena BernasconiDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.
Laura AlvaDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.
Mario SousaDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.
Ines DeboveDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0002-1709-2963
Andreas NowackiDepartment of Neurosurgery, Bern University Hospital and University of Bern, Bern, Switzerland.
Camille SerquetDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.
Katrin PetermannDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.
T A Khoa NguyenARTORG Center for Biomedical Engineering Research, University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0003-0577-5035
Andreia D MagalhãesDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.
Lenard LachenmayerDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0003-2952-6383
Julia WaskönigDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.
Tobias NefDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0002-8069-9450
Michael SchuepbachInstitute of Neurology, Konolfingen, Switzerland.
Claudio PolloDepartment of Neurosurgery, Bern University Hospital and University of Bern, Bern, Switzerland.
Paul KrackDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.
Alberto AvernaDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0001-9738-1281
Gerd TinkhauserDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.

Funding

Department of Neurology, Bern University HospitalGottfried und Julia Bangerter-Rhyner-StiftungParkinson SchweizSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 32003B_205156 / 2Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 32003BL_197709Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung PZ00P3_202166Swiss Parkinson Association
6 · The paper itself

Abstract

backgroundNovel commercial brain-sense neurostimulators enable us to contextualize brain activity with symptom and medication states in real-life ambulatory settings in Parkinson's disease (PD). Although various candidate biomarkers have been proposed for adaptive deep brain stimulation (DBS), a comprehensive comparison of their ambulatory profiles is lacking.

objectivesTo systematically compare the ambulatory neurophysiological dynamics and clinical properties of three candidate biomarkers-low-frequency, beta (β), and finely tuned γ (FTG) activity.

methodsWe investigated 14 PD patients implanted with the Medtronic Percept PC, who underwent up to two 4-week ambulatory multimodal recording periods on their regular medication and stimulation. Subthalamic nucleus local field potentials (LFPs) of low-frequency, β, and FTG activity were recorded. Additionally, objective motor symptom states, physical activity and heart rate using wearables, as well as medication-intake times, sleep-awake times, and subjective symptom states using diaries were co-registered. LFP dynamics were also compared to high-resolution in-hospital recordings under off/on dopaminergic medication and stimulation conditions.

resultsFTG reliably indexed off to on medication states in the ambulatory setting at the group and individual levels, and these spectral dynamics could be anticipated by high-resolution in-hospital recordings. Both FTG and low-frequency correlated with wearable-based dyskinesia scores, whereas diary-based dyskinesia events were only linked to FTG. Importantly, FTG indicated on-medication states regardless of the presence of dyskinesia and despite potential motion and heart rate artifacts. The 24-hour profile revealed large circadian power shifts that may overdrive medication-intake dynamics.

conclusionDespite the limitations of low-temporal resolution recordings, this work provides valuable insights into the real-life dynamics of biomarkers. Specifically, it highlights the utility of FTG as a primary and reliable indicator of medication states for adaptive DBS. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Indexed as

Antiparkinson AgentsDeep Brain StimulationGamma RhythmParkinson DiseaseSubthalamic NucleusAgedBeta RhythmFemaleHumansImplantable NeurostimulatorsMaleMiddle AgedAntiparkinson Agentsbiomarkersbrain‐senseclosed‐loop, adaptive deep brain stimulationhome recordingParkinson's disease

Identifiers

PMID40079832
PMCPMC12089918

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.